Lab

Center for Human Therapeutics: cGMP Core Facilities

The Center for Human Therapeutics (CHT) facilitates bench-to-bedside translation of preclinical biologics at the state-of-the-art current Good Manufacturing Practice (cGMP) compliant facility at the University of Virginia (UVA).
The CHT cGMP Core Facility offers:

- Clean Room Manufacturing Space
- Manufacturing Equipment
- Manufacturing Support
- Quality Control Services
- Consultation Services
- Education and Training Services

Read More

Webinar

DEI Webinar: Why Conscious Inclusion is Everyone's Responsibility?

Gamiel Yafai, who is a multi-award winning DE&I strategist, shares his insights from a 23-year career as a DEI strategist into how to elevate DEI and make it more manageable in the workplace and explore why having a greater understanding of the role that you play in driving DE&I is a must have part of your own growth and professional development. Hosted by the Center for Global Inclusion

Read More

Report

Economic Development Data on STEM Jobs

A new report titled “People of Science” provides an inclusive overview of the growing U.S. STEM workforce and its impact on the U.S. economy. The growth in STEM professions is expected to continue based on BLS predictions that STEM employment will increase by more than twice the rate of non-STEM jobs by 2031.

Read More

Report

Exits, Ecosystems, and Beyond: How To Optimize Your Startup’s Investor Relationships

Since founding CONNETT PC in 2018, we’ve been fortunate to observe, at close range, the qualities, skills, and routines of the most successful startup founders. In this article, we’ll decode how the most successful startup founders build robust founder-investor ecosystems, in addition to great companies, with the potential to generate returns for several years, if not decades, after the original startup investment.

Read More

Report

PLANNING FOR THE BIOSECURE ACT by Foley Hoag

Key Takeaways: The BIOSECURE Act, moving through the U.S. House and Senate, may restrict U.S. life sciences companies from contracting with biotech firms linked to the Chinese government or other "foreign adversaries." This legislation would bar the U.S. government from contracting with "biotechnology companies of concern" and prevent federally funded companies from engaging with these entities. Affected companies might have to choose between maintaining these relationships or federal contracts. Life sciences companies working with WuXi AppTec, BGI Group, MGI, Complete Genomics, or others with ties to China, Russia, North Korea, or Iran, should monitor the legislation and plan to mitigate potential impacts, considering the long lead times in biotech services and equipment. Although still under consideration, the bill has strong bipartisan support and national security backing, making it likely to become law in 2024.

Read More

Lab

UVA Engineering IFAB Laboratory Instrumentation

Innovations in Fabrication offers state-of-the-art instruments, including a $10 million investment in specialized microfabrication tools, plus our one-of-a-kind, custom-built fabrication systems.

Read More